

27 May

5704

105

-----Original Message-----

Jeff-
Could you approve this sequence search? Each sequence is an antisense targeted to the same gene. Thank-you!
Karen

Please perform a sequence search in the commercial databases on the following sequences for 09/975,123. Please perform the search as a **length limited search**, please limit the length of oligonucleotides to less than 100 nucleotides long:

13-19, 21, 23-36, and 38-43

Thank-you!

Point of Contact:
Toby Port
Technical Info. Specialist
CM14E01 TEL: 308-3534
12C4

CM1 11D09 GAU 1635
(703) 308-7523

mailbox 11E12

Searcher: _____	TYPE OF SEARCH: _____
Phone: _____	NA Sequences: <u>28</u>
Location: _____	AA Sequences: _____
	Structures: _____
	Other: _____

VENDOR/COST(where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRIlink: _____
WWW:Internet
Other (specify): _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Name JANE ZARA Accession # 77512 Date 8/12/03
 Accession # 1635 PFI# 6-5820 Serial Number 09/975,123
 Accession # 11003 Preferred File PAPER DISK EMAIL

If more than one search is submitted, please prioritize searches in order of need. 11E12

Please provide a brief statement of the search topic and describe as precisely as possible the subject matter to be searched. Include the chemical, physical structures, key words, synonyms, acronyms, and tag line numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention Freier
 Inventors (please print last names) ASG ILGFBP5

Earliest Priority Filing Date 10/9/01

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search Seq ID #'s:
15, 23, 24, 26-30
33-36, 38-43.

For Interference + regular data base.
 — Limit ^{ALL} TO 100 NT's. ONLY.
 Thanks.

* These seq have been searched together before.

STAFF USE ONLY

Slipman

Type of Search

NA Sequence #

AA Sequence #

Structure #

Bio-graphic #

Other #

Vendors and cost where applicable

NA

AA

Structure

Bio-graphic

Other

9/12/03

```

set      items      description
s1       150        IGF1R (S) IGF W HPS
s2       14         S1 (S) (ANTISENSE OR RIBOZYME?)
s3       3          RD (unique items)
s4       14         S1 AND (ANTISENSE OR RIBOZYME?)
s5       4          RD (unique items)
s6       1400       INSULIN (W) LIKE (W) GROWTH (W) FACTOR (W) BINDING (W) PRO-
                    TEIN (W) S
s7       11         S6 (S) (ANTISENSE OR RIBOZYME?)
s8       4          RD (unique items)
s9       42         S6 AND (ANTISENSE OR RIBOZYME?)
s10      17         RD (unique items)
>>>KWIC option is not available in file(s): 41, 42, 399

```

10/3,K/1 (Item 1 from file: 5)
 DIALOG(R)File 5: Biosis Previews(R)
 (c) 2002 BIOSIS. All rts. reserv.

13216933 BIOSIS NC.: 200100424132

The IGF/IGFBP system in CNS malignancy.

AUTHOR: Zumkeller W(a); Westphal M

AUTHOR ADDRESS: (a)Department of Pediatrics, Martin-Luther-University
 Halle-Wittenberg, University Hospital, Ernst-Grube-Str. 40, 06097,
 Halle/Saale: walter.zumkeller@medizin.uni-halle.de**Germany

JOURNAL: Molecular Pathology 54 (4):p227-229 August, 2001

MEDIUM: print

ISSN: 1366-8714

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

...ABSTRACT: Both types of IGF receptor are expressed in gliomas and, in particular, the type I IGF receptor appears to be upregulated in malignant brain tissue. *Antisense* IGF-I receptor mRNA induces an antitumour response, resulting in complete brain tumour regression. Clinical trials for the treatment of brain tumours in humans based on a gene transfer protocol using IGF-I receptor *antisense* are under way. All six IGFBPs are expressed to a variable extent in brain tumours. High concentrations of IGFBP-2 are found in cerebrospinal fluid...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: *antisense* insulin-like growth factor-I receptor messenger RNA...

...*insulin*-*like* *growth* *factor* *binding* *protein*-*5*;

10/3,K/2 (Item 2 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

13216933 BIOSIS NC.: 200100424132

Castration-induced up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5* potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.

AUTHOR: Miyake Hideaki; Pollak Michael; Gleave Martin E(a)

AUTHOR ADDRESS: (a)Division of Urology, University of British Columbia,
 P-2, 1033 Heather Street, Vancouver, BC, V6Z 3J5**Canada

JOURNAL: Cancer Research 61 (11):p3001-3004 June 1, 2001

MEDIUM: print

Castration-induced up-regulation of *insulin*-*like* *growth* *factor*

***binding* *protein*--*5* potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.**

ABSTRACT: Although *insulin*--*like* *growth* *factor* *binding* *protein*--*5* (IGFBP-5) has been shown to be implicated in prostate cancer progression, the functional role of IGFBP-5 in progression to androgen-independence remains largely...

...cells were stably transfected with IGFBP-5 gene, and IGFBP-5-overexpressing LNCaP tumors progressed significantly faster to androgen independence after castration compared with controls. *Antisense* mouse IGFBP-5 oligodeoxynucleotides (ODNs) were then designed that reduced IGFBP-5 expression in Shionogi tumor cells in vitro in a dose-dependent and sequence-specific manner. Growth of Shionogi tumor cells was inhibited by *antisense* IGFBP-5 ODN treatment in a time- and dose-dependent manner, which could be reversed by exogenous IGF-I. However, *antisense* IGFBP-5 ODN treatment had no additive inhibitory effect on Shionogi tumor cell growth when IGF-I activity was neutralized by anti-IGF-I antibody. *Antisense* IGFBP-5 ODN treatment resulted in decreased mitogen-activated protein kinase activity and number of cells in the S + G2-M phases of the cell cycle that directly correlated with reduced proliferation rate of Shionogi tumor cells. Systemic administration of *antisense* IGFBP-5 ODN in mice bearing Shionogi tumors after castration significantly delayed time to progression to androgen independence and inhibited growth of AI recurrent tumors...

...serves to enhance IGF bioactivity and raise the possibility that the response of prostate cancer to androgen withdrawal can be enhanced by strategies, such as *antisense* IGFBP-5 ODN therapy, that target IGF signal transduction.

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*--*like* *growth* *factor* *binding* *protein*--*5*--...

...human IGFBP-5 gene {human *insulin*--*like* *growth* *factor* *binding* *protein*--*5* gene} (Hominidae)

10/3,K/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12099757 BIOSIS NO.: 199900394606

Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins.

AUTHOR: Rosen Florence; Pollak Michael(a)

AUTHOR ADDRESS: (a) Lady Davis Institute for Medical Research of the Jewish General Hospital, 3755 Cote Ste. Catherine**Canada

JOURNAL: International Journal of Oncology 15 (3):p589-594 Sept., 1999

ISSN: 1171-4644

KEYWORD: IGF: Antagonist

KEYWORD: IGF: Antagonist

LANGUAGE: English

SUMMARY LANGUAGE: English

...**ABSTRACT:** At IRS-1 induced by des(1-3) IGF-I, and IGF-I analogue with greatly reduced activity for IGF-1s. Furthermore, we demonstrate that an *antisense* IGFBP-5 oligodeoxynucleotide attenuates EB1089-induced inhibition of IGF-I-stimulated tyrosine phosphorylation of IRS-1 and PI3K--induced IGF-1 stimulation. These data strongly...

KEYWORDS:

11842922 BIOSIS NO.: 199800069031

**Differential expression and localization of IGF-I and IGF binding proteins
in inflamed rat colon.**

AUTHOR: Seeh Joerg E; Mahapatra Niru; Lund F Kay; Eysselein Viktor E;
McRoberts James A

AUTHOR ADDRESS: Harbor-UCLA Med. Cent., Div. Gastroenterol., Torrance, CA
**USA

JOURNAL: Journal of Receptor and Signal Transduction Research 18 (4-6):p
265-280 July-Nov., 1998

ISSN: 1079-9893

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: were sacrificed at 7 days after induction of colitis. Cryostat
sections of colon from TNB-treated and control rats were hybridized with
35 S-labeled *antisense* probes for IGF-1k, IGFBP-3, IGFBP-4 and IGFBP-5.
IGF-1 mRNA was up-regulated in lamina propria cells, submucosa and smooth
muscle...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*-*like* *growth* *factor*
binding *protein*-*5*--

10/3,K/5 (Item 5 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

11424292 BIOSIS NO.: 199800209624

**Up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5*
is independent of muscle cell differentiation, sensitive to rapamycin,
but insensitive to wortmannin and LY294002.**

AUTHOR: Rousse Sophie; Montarras Didier; Finset Christian; Dukcis Catherine
(a)

AUTHOR ADDRESS: (a)Inst. Natl. Sante Recherche Med., U.142, Hop. Saint
Antoine, 75571 Paris Cedex 12**France

JOURNAL: Endocrinology 139 (4):p1487-1493 April, 1998

ISSN: 0013-7227

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**Up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5*
is independent of muscle cell differentiation, sensitive to rapamycin,
but insensitive to wortmannin and LY294002.**

...ABSTRACT: and modulated by IGF binding proteins (IGFBPs) secreted by the
cells. The mouse C2 myoblast cell line stably transfected with a vector
producing IGF-II *antisense* RNA was used to show that specific IGFBP
expression changes with the state of the cells: high levels of IGFBP-1
messenger RNA (mRNA) were...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*-*like* *growth* *factor* *binding*
protein-*5*--

10/3,K/6 (Item 6 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

JOURNAL: Human Growth Hormone Basel 4: 1991.1:pl: 1-47
CONFERENCE MEETING: 5th Joint Meeting of the European Society for
Paediatric Endocrinology and the Lawson Wilkins Society for Pediatric
Endocrinology, in Collaboration with the Australian Paediatric Endocrine
Group, the Japanese Society for Pediatric Endocrinology and the Latin
American Society for Paediatric Endocrinology Stockholm, Sweden June
22-26, 1990
ISSN: 0301-0103
RECORD TYPE: Citation
LANGUAGE: English

MISCELLANEOUS TERMS: ...INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3
ANTISENSE OLIGONUCLEOTIDE...
...INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 *ANTISENSE* OLIGONUCLEOTIDE
...

...*INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5*;

10/3,K/7 (Item 7 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10730630 BIOSIS NO.: 199799321775

**A role for *insulin*-*like* *growth* *factor* *binding* *protein* *5* in
the antiproliferative action of the antiestrogen ICI 182780.**

AUTHOR: Huynh Hung(a); Yang Xiao-Peng; Pollak Michael
AUTHOR ADDRESS: (a)Dep. Med., McGill Univ., 3755 Cote Ste Catherine Rd.,
Montreal, PQ H3T 1E2**Canada
JOURNAL: Cell Growth & Differentiation 7 (11):p1501-1506 1996
ISSN: 1044-9523
RECORD TYPE: Abstract
LANGUAGE: English

**A role for *insulin*-*like* *growth* *factor* *binding* *protein* *5* in
the antiproliferative action of the antiestrogen ICI 182780.**

...ABSTRACT: mRNA abundance, and increased IGFBP-5 protein accumulation in
the conditioned medium. Growth stimulation following estradiol exposure
was associated with opposite effects. An IGFBP-5 *antisense*
oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in
conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore,
this *antisense* oligodeoxynucleotide attenuated both
antiestrogen-induced IGFBP-5 accumulation and antiestrogen-induced growth
inhibition. These data demonstrate that estradiol down-regulates and ICI
up-regulates an...

MISCELLANEOUS TERMS: ...*INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING*
PROTEIN *5*;*INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*
5 mRNA

10/3,K/8 (Item 8 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10740630 BIOSIS NO.: 199800000000

**Osteogenic protein-1-mediated insulin-like growth factor gene expression in
primary cultures of rat osteoblastic cells.**

AUTHOR: Yeh Lee-Chuan C (a); Aima Martin I; Kitten Allison M; Olson Merle C
(a); Olson Merle C
AUTHOR ADDRESS: (a)Dep. Pathol., Univ. Texas Health Sci. Cent., 7701 Fwy 1
Dallas, TX 75390-3000

...ABSTRACT: a concentration-dependent manner. The IGFBP-4, -5, and -6 mRNA levels decreased dramatically in an IGF-1 concentration-dependent manner. In addition, colocalization of *antisense* oligonucleotides corresponding to IGF-1 or -II mRNA sequence with IGF-1 reduced the IGF-1-induced elevation in alkaline phosphatase activity. The present results...
MISCELLANEOUS TERMS: ...*INSULIN*-like* *GROWTH* *FACTOR*-binding*
PROTEIN-5*;

10/3,K/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10381965 BIOSIS NO.: 199699004110

***Insulin*-like* *growth* *factor* *binding* *protein*-5* modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.**

AUTHOR: James Payton L; Stewart Claire E H; Rotwein Peter
AUTHOR ADDRESS: Dep. Biochemistry Molecular Biophysics, 660 South Euclid Ave., Box 8231, St. Louis, MO 63110*USA
JOURNAL: Journal of Cell Biology 133 (3):p683-693 1996
ISSN: 0021-9529
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

***Insulin*-like* *growth* *factor* *binding* *protein*-5* modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.**

...ABSTRACT: sense myoblasts show enhanced survival in low serum medium, remaining viable for at least four weeks in culture. By contrast, myoblasts expressing the IGFBP-5 *antisense* transcript differentiate prematurely and more extensively than control cells. The inhibition of myogenic differentiation by high level expression of IGFBP-5 could be overcome by...

10/3,K/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09598075 BIOSIS NO.: 199598049993

Localization of messenger ribonucleic acid for insulin-like growth factor-binding proteins in human skin by in situ hybridization.

AUTHOR: Batch J A(a); Mercuri F A; Edmondson S R; Werther G A
AUTHOR ADDRESS: (a)Cent. Hormone Res., Royal Children's Hosp., Flemington Rd., Parkville, 3052 VIC*Australia
JOURNAL: Journal of Clinical Endocrinology & Metabolism 79 (5):p1444-1449 1994
ISSN: 0724-9460
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: Immunohistochemical localization of IGFs in human skin, we have used in situ hybridization to localize messenger ribonucleic acid (mRNA) for the six IGFs. *Antisense* and sense RNA probes for the IGFs: IGF-I, -II, -III, -IV, -V, and -VI were used, and 10-um-thick sections of normal adult human skin were examined...
MISCELLANEOUS TERMS: ...*INSULIN*-like* *GROWTH* *FACTOR*-binding*
PROTEIN-5*;

Increased expression of IGF-binding protein-5 in Duchenne muscular dystrophy (DMD) fibroblasts correlates with the fibroblast-induced downregulation of DMD myoblast growth: an in vitro analysis.

Melone M A; Poluso G; Galderisi U; Pettiti G; Cetraro A
Second Division of Neurology, Second University of Naples, School of Medicine, Naples, Italy. marina.melone@unina2.it

Journal of Cellular Physiology 187(1):143-53, Oct 2000, 141 [1] p143-53, ISSN 0021-9541 Journal Code: JCB222

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... IGF-BP-5 in DMD fibroblast-conditioned media by means of specific antibodies, or inhibiting IGF-BP-5 gene expression in DMD fibroblasts by means of oligo antisense, the fibroblast-conditioned media lost inhibitory power over DMD myoblast proliferation. Copyright 2000 Wiley-Liss, Inc.

Descriptors: Fibroblasts--metabolism--ME; *Fibroblasts--pathology--PA; *Insulin--*Like *Growth--*Factor--*Binding--*Protein *5--biosynthesis--BI; *Muscle, Skeletal--metabolism--ME; *Muscle, Skeletal--pathology--PA; *Muscular Dystrophy, Duchenne--metabolism--ME; *Muscular Dystrophy, Duchenne--pathology--PA

Chemical Name: Culture Media, Conditioned; *Insulin--*Like *Growth--*Factor--*Binding--*Protein *5*

10/3,K/12 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

08764041 96109186 PMID: 8618825

Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells.

Steller M A; Delgado C H; Zou Z

Section of Gynecologic Oncology, National Cancer Institute, Bethesda, MD 20892-1502, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Dec 19 1995, 92 (26) p11970-4, ISSN 0027-8424 Journal Code: 7505876

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... induced mitogenesis was abrogated in a dose-dependent manner by IGF-binding protein 5 (IGFBP-5), which binds to IGF-II and neutralizes it. An antisense oligonucleotide to IGF-II also inhibited the proliferative response to EGF. In addition, prolonged, but not short-term, stimulation with EGF resulted in autophosphorylation of...

Descriptors: Epidermal Growth Factor--pathology--PA; *Epidermal Growth Factor--pharmacology--PI; *Insulin-like Growth Factor II--biosynthesis--BI; *Insulin-like Growth Factor II--pharmacology--PI; *Mitogenesis, Antisense--pharmacology--PI; *Mitogenesis--drug effects--DE; *Insulin-like Growth Factor II--biosynthesis--BI; *Insulin-like Growth Factor II--metabolism--ME; *Insulin-like Growth Factor II--pharmacology--PI; *Insulin--*Like *Growth--*Factor--*Binding--*Protein *5--pharmacology--PI; Kinetics; Mitosis--drug effects--DE; Molecular Sequence Data; Oligodeoxynucleotides--pharmacology--PI; RNA, Messenger--metabolism--ME; Receptor, IGF Type I--metabolism--ME; Tumor Cells...

Chemical Name: *Insulin--*Like *Growth--*Factor--*Binding--*Protein *5; Oligodeoxynucleotides; Oligonucleotides, Antisense; RNA, Messenger;

10/3, K/14 (Item 1 from file: 399)

Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries.

el-Roeily A; Chen X; Roberts V J; Shimasakai S; Ling N; LeRoith D; Roberts C T; Yen S S

Department of Reproductive Medicine, University of California School of Medicine, La Jolla 92035.

Journal of clinical endocrinology and metabolism (UNITED STATES) Jun 1994; 78: 1481-1486, ISSN 0021-472X Journal Code: 0375362

Abstract Grant No.: HL-37113-1; HL; NIDHD; HD-37113-11; HD; NICHD; HD-14303-10; HL; NIDHD

Document type: Journal Article

Language: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... in specific cellular compartments of normal and PCOS human ovaries. Messenger ribonucleic acid (mRNA) was localized by in situ hybridization with specific 35S-labeled human *antisense* RNA probes, and protein was detected by immunohistochemistry using specific antisera. Thecal cells, but not granulosa cells (GC), of small antral follicles (3-6 mm...

...; Growth Factor II--analysis--AN; Insulin-Like Growth Factor-Binding Protein 2; Insulin-Like Growth-Factor Binding Protein 1; Insulin-Like Growth-Factor-Binding Proteins; *Insulin*--*Like* *Growth*--*Factor*--*Binding*--*Protein* *5*; Insulin-Like-Growth Factor Binding Protein 6; Middle Age; Ovary--pathology--PA; Polycystic Ovary Syndrome--pathology--PA; RNA Probes; Receptor, IGF Type 1--analysis--AN...

...Chemical Name: Growth-Factor-Binding Protein 4; Insulin-Like Growth Factor-Binding Protein 2; Insulin-Like Growth-Factor Binding Protein 1; Insulin-Like Growth-Factor-Binding Proteins; *Insulin*--*Like* *Growth*--*Factor*--*Binding*--*Protein* *5*; Insulin-Like-Growth-Factor-Binding Protein 6; RNA Probes; RNA, Messenger; Receptor, IGF Type 2; Insulin-Like Growth Factor 1; Insulin-Like Growth Factor II...

10/3, K/14 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft

LOCATION: Den.

ASSIGNEE: Come Biotech Aps

PATENT: ECT International ; WO 200232953 A2 DATE: 20020425

APPLICATION: WO 2001000000 (20010101) *EP 1 111001 (20001020) *US 10241840

CLASS: C12N 1/21; C12N 1/22; C12N 1/23; C12N 1/24; C12N 1/25; C12N 1/26; C12N 1/27; C12N 1/28; C12N 1/29; C12N 1/30; C12N 1/31; C12N 1/32; C12N 1/33; C12N 1/34; C12N 1/35; C12N 1/36; C12N 1/37; C12N 1/38; C12N 1/39; C12N 1/40; C12N 1/41; C12N 1/42; C12N 1/43; C12N 1/44; C12N 1/45; C12N 1/46; C12N 1/47; C12N 1/48; C12N 1/49; C12N 1/50; C12N 1/51; C12N 1/52; C12N 1/53; C12N 1/54; C12N 1/55; C12N 1/56; C12N 1/57; C12N 1/58; C12N 1/59; C12N 1/60; C12N 1/61; C12N 1/62; C12N 1/63; C12N 1/64; C12N 1/65; C12N 1/66; C12N 1/67; C12N 1/68; C12N 1/69; C12N 1/70; C12N 1/71; C12N 1/72; C12N 1/73; C12N 1/74; C12N 1/75; C12N 1/76; C12N 1/77; C12N 1/78; C12N 1/79; C12N 1/80; C12N 1/81; C12N 1/82; C12N 1/83; C12N 1/84; C12N 1/85; C12N 1/86; C12N 1/87; C12N 1/88; C12N 1/89; C12N 1/90; C12N 1/91; C12N 1/92; C12N 1/93; C12N 1/94; C12N 1/95; C12N 1/96; C12N 1/97; C12N 1/98; C12N 1/99; C12N 2/00; C12N 2/01; C12N 2/02; C12N 2/03; C12N 2/04; C12N 2/05; C12N 2/06; C12N 2/07; C12N 2/08; C12N 2/09; C12N 2/10; C12N 2/11; C12N 2/12; C12N 2/13; C12N 2/14; C12N 2/15; C12N 2/16; C12N 2/17; C12N 2/18; C12N 2/19; C12N 2/20; C12N 2/21; C12N 2/22; C12N 2/23; C12N 2/24; C12N 2/25; C12N 2/26; C12N 2/27; C12N 2/28; C12N 2/29; C12N 2/30; C12N 2/31; C12N 2/32; C12N 2/33; C12N 2/34; C12N 2/35; C12N 2/36; C12N 2/37; C12N 2/38; C12N 2/39; C12N 2/40; C12N 2/41; C12N 2/42; C12N 2/43; C12N 2/44; C12N 2/45; C12N 2/46; C12N 2/47; C12N 2/48; C12N 2/49; C12N 2/50; C12N 2/51; C12N 2/52; C12N 2/53; C12N 2/54; C12N 2/55; C12N 2/56; C12N 2/57; C12N 2/58; C12N 2/59; C12N 2/60; C12N 2/61; C12N 2/62; C12N 2/63; C12N 2/64; C12N 2/65; C12N 2/66; C12N 2/67; C12N 2/68; C12N 2/69; C12N 2/70; C12N 2/71; C12N 2/72; C12N 2/73; C12N 2/74; C12N 2/75; C12N 2/76; C12N 2/77; C12N 2/78; C12N 2/79; C12N 2/80; C12N 2/81; C12N 2/82; C12N 2/83; C12N 2/84; C12N 2/85; C12N 2/86; C12N 2/87; C12N 2/88; C12N 2/89; C12N 2/90; C12N 2/91; C12N 2/92; C12N 2/93; C12N 2/94; C12N 2/95; C12N 2/96; C12N 2/97; C12N 2/98; C12N 2/99; C12N 3/00; C12N 3/01; C12N 3/02; C12N 3/03; C12N 3/04; C12N 3/05; C12N 3/06; C12N 3/07; C12N 3/08; C12N 3/09; C12N 3/10; C12N 3/11; C12N 3/12; C12N 3/13; C12N 3/14; C12N 3/15; C12N 3/16; C12N 3/17; C12N 3/18; C12N 3/19; C12N 3/20; C12N 3/21; C12N 3/22; C12N 3/23; C12N 3/24; C12N 3/25; C12N 3/26; C12N 3/27; C12N 3/28; C12N 3/29; C12N 3/30; C12N 3/31; C12N 3/32; C12N 3/33; C12N 3/34; C12N 3/35; C12N 3/36; C12N 3/37; C12N 3/38; C12N 3/39; C12N 3/40; C12N 3/41; C12N 3/42; C12N 3/43; C12N 3/44; C12N 3/45; C12N 3/46; C12N 3/47; C12N 3/48; C12N 3/49; C12N 3/50; C12N 3/51; C12N 3/52; C12N 3/53; C12N 3/54; C12N 3/55; C12N 3/56; C12N 3/57; C12N 3/58; C12N 3/59; C12N 3/60; C12N 3/61; C12N 3/62; C12N 3/63; C12N 3/64; C12N 3/65; C12N 3/66; C12N 3/67; C12N 3/68; C12N 3/69; C12N 3/70; C12N 3/71; C12N 3/72; C12N 3/73; C12N 3/74; C12N 3/75; C12N 3/76; C12N 3/77; C12N 3/78; C12N 3/79; C12N 3/80; C12N 3/81; C12N 3/82; C12N 3/83; C12N 3/84; C12N 3/85; C12N 3/86; C12N 3/87; C12N 3/88; C12N 3/89; C12N 3/90; C12N 3/91; C12N 3/92; C12N 3/93; C12N 3/94; C12N 3/95; C12N 3/96; C12N 3/97; C12N 3/98; C12N 3/99; C12N 4/00; C12N 4/01; C12N 4/02; C12N 4/03; C12N 4/04; C12N 4/05; C12N 4/06; C12N 4/07; C12N 4/08; C12N 4/09; C12N 4/10; C12N 4/11; C12N 4/12; C12N 4/13; C12N 4/14; C12N 4/15; C12N 4/16; C12N 4/17; C12N 4/18; C12N 4/19; C12N 4/20; C12N 4/21; C12N 4/22; C12N 4/23; C12N 4/24; C12N 4/25; C12N 4/26; C12N 4/27; C12N 4/28; C12N 4/29; C12N 4/30; C12N 4/31; C12N 4/32; C12N 4/33; C12N 4/34; C12N 4/35; C12N 4/36; C12N 4/37; C12N 4/38; C12N 4/39; C12N 4/40; C12N 4/41; C12N 4/42; C12N 4/43; C12N 4/44; C12N 4/45; C12N 4/46; C12N 4/47; C12N 4/48; C12N 4/49; C12N 4/50; C12N 4/51; C12N 4/52; C12N 4/53; C12N 4/54; C12N 4/55; C12N 4/56; C12N 4/57; C12N 4/58; C12N 4/59; C12N 4/60; C12N 4/61; C12N 4/62; C12N 4/63; C12N 4/64; C12N 4/65; C12N 4/66; C12N 4/67; C12N 4/68; C12N 4/69; C12N 4/70; C12N 4/71; C12N 4/72; C12N 4/73; C12N 4/74; C12N 4/75; C12N 4/76; C12N 4/77; C12N 4/78; C12N 4/79; C12N 4/80; C12N 4/81; C12N 4/82; C12N 4/83; C12N 4/84; C12N 4/85; C12N 4/86; C12N 4/87; C12N 4/88; C12N 4/89; C12N 4/90; C12N 4/91; C12N 4/92; C12N 4/93; C12N 4/94; C12N 4/95; C12N 4/96; C12N 4/97; C12N 4/98; C12N 4/99; C12N 5/00; C12N 5/01; C12N 5/02; C12N 5/03; C12N 5/04; C12N 5/05; C12N 5/06; C12N 5/07; C12N 5/08; C12N 5/09; C12N 5/10; C12N 5/11; C12N 5/12; C12N 5/13; C12N 5/14; C12N 5/15; C12N 5/16; C12N 5/17; C12N 5/18; C12N 5/19; C12N 5/20; C12N 5/21; C12N 5/22; C12N 5/23; C12N 5/24; C12N 5/25; C12N 5/26; C12N 5/27; C12N 5/28; C12N 5/29; C12N 5/30; C12N 5/31; C12N 5/32; C12N 5/33; C12N 5/34; C12N 5/35; C12N 5/36; C12N 5/37; C12N 5/38; C12N 5/39; C12N 5/40; C12N 5/41; C12N 5/42; C12N 5/43; C12N 5/44; C12N 5/45; C12N 5/46; C12N 5/47; C12N 5/48; C12N 5/49; C12N 5/50; C12N 5/51; C12N 5/52; C12N 5/53; C12N 5/54; C12N 5/55; C12N 5/56; C12N 5/57; C12N 5/58; C12N 5/59; C12N 5/60; C12N 5/61; C12N 5/62; C12N 5/63; C12N 5/64; C12N 5/65; C12N 5/66; C12N 5/67; C12N 5/68; C12N 5/69; C12N 5/70; C12N 5/71; C12N 5/72; C12N 5/73; C12N 5/74; C12N 5/75; C12N 5/76; C12N 5/77; C12N 5/78; C12N 5/79; C12N 5/80; C12N 5/81; C12N 5/82; C12N 5/83; C12N 5/84; C12N 5/85; C12N 5/86; C12N 5/87; C12N 5/88; C12N 5/89; C12N 5/90; C12N 5/91; C12N 5/92; C12N 5/93; C12N 5/94; C12N 5/95; C12N 5/96; C12N 5/97; C12N 5/98; C12N 5/99; C12N 6/00; C12N 6/01; C12N 6/02; C12N 6/03; C12N 6/04; C12N 6/05; C12N 6/06; C12N 6/07; C12N 6/08; C12N 6/09; C12N 6/10; C12N 6/11; C12N 6/12; C12N 6/13; C12N 6/14; C12N 6/15; C12N 6/16; C12N 6/17; C12N 6/18; C12N 6/19; C12N 6/20; C12N 6/21; C12N 6/22; C12N 6/23; C12N 6/24; C12N 6/25; C12N 6/26; C12N 6/27; C12N 6/28; C12N 6/29; C12N 6/30; C12N 6/31; C12N 6/32; C12N 6/33; C12N 6/34; C12N 6/35; C12N 6/36; C12N 6/37; C12N 6/38; C12N 6/39; C12N 6/40; C12N 6/41; C12N 6/42; C12N 6/43; C12N 6/44; C12N 6/45; C12N 6/46; C12N 6/47; C12N 6/48; C12N 6/49; C12N 6/50; C12N 6/51; C12N 6/52; C12N 6/53; C12N 6/54; C12N 6/55; C12N 6/56; C12N 6/57; C12N 6/58; C12N 6/59; C12N 6/60; C12N 6/61; C12N 6/62; C12N 6/63; C12N 6/64; C12N 6/65; C12N 6/66; C12N 6/67; C12N 6/68; C12N 6/69; C12N 6/70; C12N 6/71; C12N 6/72; C12N 6/73; C12N 6/74; C12N 6/75; C12N 6/76; C12N 6/77; C12N 6/78; C12N 6/79; C12N 6/80; C12N 6/81; C12N 6/82; C12N 6/83; C12N 6/84; C12N 6/85; C12N 6/86; C12N 6/87; C12N 6/88; C12N 6/89; C12N 6/90; C12N 6/91; C12N 6/92; C12N 6/93; C12N 6/94; C12N 6/95; C12N 6/96; C12N 6/97; C12N 6/98; C12N 6/99; C12N 7/00; C12N 7/01; C12N 7/02; C12N 7/03; C12N 7/04; C12N 7/05; C12N 7/06; C12N 7/07; C12N 7/08; C12N 7/09; C12N 7/10; C12N 7/11; C12N 7/12; C12N 7/13; C12N 7/14; C12N 7/15; C12N 7/16; C12N 7/17; C12N 7/18; C12N 7/19; C12N 7/20; C12N 7/21; C12N 7/22; C12N 7/23; C12N 7/24; C12N 7/25; C12N 7/26; C12N 7/27; C12N 7/28; C12N 7/29; C12N 7/30; C12N 7/31; C12N 7/32; C12N 7/33; C12N 7/34; C12N 7/35; C12N 7/36; C12N 7/37; C12N 7/38; C12N 7/39; C12N 7/40; C12N 7/41; C12N 7/42; C12N 7/43; C12N 7/44; C12N 7/45; C12N 7/46; C12N 7/47; C12N 7/48; C12N 7/49; C12N 7/50; C12N 7/51; C12N 7/52; C12N 7/53; C12N 7/54; C12N 7/55; C12N 7/56; C12N 7/57; C12N 7/58; C12N 7/59; C12N 7/60; C12N 7/61; C12N 7/62; C12N 7/63; C12N 7/64; C12N 7/65; C12N 7/66; C12N 7/67; C12N 7/68; C12N 7/69; C12N 7/70; C12N 7/71; C12N 7/72; C12N 7/73; C12N 7/74; C12N 7/75; C12N 7/76; C12N 7/77; C12N 7/78; C12N 7/79; C12N 7/80; C12N 7/81; C12N 7/82; C12N 7/83; C12N 7/84; C12N 7/85; C12N 7/86; C12N 7/87; C12N 7/88; C12N 7/89; C12N 7/90; C12N 7/91; C12N 7/92; C12N 7/93; C12N 7/94; C12N 7/95; C12N 7/96; C12N 7/97; C12N 7/98; C12N 7/99; C12N 8/00; C12N 8/01; C12N 8/02; C12N 8/03; C12N 8/04; C12N 8/05; C12N 8/06; C12N 8/07; C12N 8/08; C12N 8/09; C12N 8/10; C12N 8/11; C12N 8/12; C12N 8/13; C12N 8/14; C12N 8/15; C12N 8/16; C12N 8/17; C12N 8/18; C12N 8/19; C12N 8/20; C12N 8/21; C12N 8/22; C12N 8/23; C12N 8/24; C12N 8/25; C12N 8/26; C12N 8/27; C12N 8/28; C12N 8/29; C12N 8/30; C12N 8/31; C12N 8/32; C12N 8/33; C12N 8/34; C12N 8/35; C12N 8/36; C12N 8/37; C12N 8/38; C12N 8/39; C12N 8/40; C12N 8/41; C12N 8/42; C12N 8/43; C12N 8/44; C12N 8/45; C12N 8/46; C12N 8/47; C12N 8/48; C12N 8/49; C12N 8/50; C12N 8/51; C12N 8/52; C12N 8/53; C12N 8/54; C12N 8/55; C12N 8/56; C12N 8/57; C12N 8/58; C12N 8/59; C12N 8/60; C12N 8/61; C12N 8/62; C12N 8/63; C12N 8/64; C12N 8/65; C12N 8/66; C12N 8/67; C12N 8/68; C12N 8/69; C12N 8/70; C12N 8/71; C12N 8/72; C12N 8/73; C12N 8/74; C12N 8/75; C12N 8/76; C12N 8/77; C12N 8/78; C12N 8/79; C12N 8/80; C12N 8/81; C12N 8/82; C12N 8/83; C12N 8/84; C12N 8/85; C12N 8/86; C12N 8/87; C12N 8/88; C12N 8/89; C12N 8/90; C12N 8/91; C12N 8/92; C12N 8/93; C12N 8/94; C12N 8/95; C12N 8/96; C12N 8/97; C12N 8/98; C12N 8/99; C12N 9/00; C12N 9/01; C12N 9/02; C12N 9/03; C12N 9/04; C12N 9/05; C12N 9/06; C12N 9/07; C12N 9/08; C12N 9/09; C12N 9/10; C12N 9/11; C12N 9/12; C12N 9/13; C12N 9/14; C12N 9/15; C12N 9/16; C12N 9/17; C12N 9/18; C12N 9/19; C12N 9/20; C12N 9/21; C12N 9/22; C12N 9/23; C12N 9/24; C12N 9/25; C12N 9/26; C12N 9/27; C12N 9/28; C12N 9/29; C12N 9/30; C12N 9/31; C12N 9/32; C12N 9/33; C12N 9/34; C12N 9/35; C12N 9/36; C12N 9/37; C12N 9/38; C12N 9/39; C12N 9/40; C12N 9/41; C12N 9/42; C12N 9/43; C12N 9/44; C12N 9/45; C12N 9/46; C12N 9/47; C12N 9/48; C12N 9/49; C12N 9/50; C12N 9/51; C12N 9/52; C12N 9/53; C12N 9/54; C12N 9/55; C12N 9/56; C12N 9/57; C12N 9/58; C12N 9/59; C12N 9/60; C12N 9/61; C12N 9/62; C12N 9/63; C12N 9/64; C12N 9/65; C12N 9/66; C12N 9/67; C12N 9/68; C12N 9/69; C12N 9/70; C12N 9/71; C12N 9/72; C12N 9/73; C12N 9/74; C12N 9/75; C12N 9/76; C12N 9/77; C12N 9/78; C12N 9/79; C12N 9/80; C12N 9/81; C12N 9/82; C12N 9/83; C12N 9/84; C12N 9/85; C12N 9/86; C12N 9/87; C12N 9/88; C12N 9/89; C12N 9/90; C12N 9/91; C12N 9/92; C12N 9/93; C12N 9/94; C12N 9/95; C12N 9/96; C12N 9/97; C12N 9/98; C12N 9/99; C12N 10/00; C12N 10/01; C12N 10/02; C12N 10/03; C12N 10/04; C12N 10/05; C12N 10/06; C12N 10/07; C12N 10/08; C12N 10/09; C12N 10/10; C12N 10/11; C12N 10/12; C12N 10/13; C12N 10/14; C12N 10/15; C12N 10/16; C12N 10/17; C12N 10/18; C12N 10/19; C12N 10/20; C12N 10/21; C12N 10/22; C12N 10/23; C12N 10/24; C12N 10/25; C12N 10/26; C12N 10/27; C12N 10/28; C12N 10/29; C12N 10/30; C12N 10/31; C12N 10/32; C12N 10/33; C12N 10/34; C12N 10/35; C12N 10/36; C12N 10/37; C12N 10/38; C12N 10/39; C12N 10/40; C12N 10/41; C12N 10/42; C12N 10/43; C12N 10/44; C12N 10/45; C12N 10/46; C12N 10/47; C12N 10/48; C12N 10/49; C12N 10/50; C12N 10/51; C12N 10/52; C12N 10/53; C12N 10/54; C12N 10/55; C12N 10/56; C12N 10/57; C12N 10/58; C12N 10/59; C12N 10/60; C12N 10/61; C12N 10/62; C12N 10/63; C12N 10/64; C12N 10/65; C12N 10/66; C12N 10/67; C12N 10/68; C12N 10/69; C12N 10/70; C12N 10/71; C12N 10/72; C12N 10/73; C12N 10/74; C12N 10/75; C12N 10/76; C12N 10/77; C12N 10/78; C12N 10/79; C12N 10/80; C12N 10/81; C12N 10/82; C12N 10/83; C12N 10/84; C12N 10/85; C12N 10/86; C12N 10/87; C12N 10/88; C12N 10/89; C12N 10/90; C12N 10/91; C12N 10/92; C12N 10/93; C12N 10/94; C12N 10/95; C12N 10/96; C12N 10/97; C12N 10/98; C12N 10/99; C12N 11/00; C12N 11/01; C12N 11/02; C12N 11/03; C12N 11/04; C12N 11/05; C12N 11/06; C12N 11/07; C12N 11/08; C12N 11/09; C12N 11/10; C12N 11/11; C12N 11/12; C12N 11/13; C12N 11/14; C12N 11/15; C12N 11/16; C12N 11/17; C12N 11/18; C12N 11/19; C12N 11/20; C12N 11/21; C12N 11/22; C12N 11/23; C12N 11/24; C12N 11/25; C12N 11/26; C12N 11/27; C12N 11/28; C12N 11/29; C12N 11/30; C12N 11/31; C12N 11/32; C12N 11/33; C12N 11/34; C12N 11/35; C12N 11/36; C12N 11/37; C12N 11/38; C12N 11/39; C12N 11/40; C12N 11/41; C12N 11/42; C12N 11/43; C12N 11/44; C12N 11/45; C12N 11/46; C12N 11/47; C12N 11/48; C12N 11/49; C12N 11/50; C12N 11/51; C12N 11/52; C12N 11/53; C12N 11/54; C12N 11/55; C12N 11/56; C12N 11/57; C12N 11/58; C12N 11/59; C12N 11/60; C12N 11/61; C12N 11/62; C12N 11/63; C12N 11/64; C12N 11/65; C12N 11/66; C12N 11/67; C12N 11/68; C12N 11/69; C12N 11/70; C12N 11/71; C12N 11/72; C12N 11/73; C12N 11/74; C12N 11/75; C12N 11/76; C12N 11/77; C12N 11/78; C12N 11/79; C12N 11/80

Use of antisense nucleic acids/analogs inhibiting growth factor-mediated cell proliferation for treatment of proliferative and/or inflammatory skin disorders

INVENTOR/AUTHOR : Weir, George Arthur; Wright, Christopher John
LOCATION: Australia
ASSIGNEE: Royal Children's Hospital Research Foundation
PATENT: PCT International ; WO 96/036 A1 DATE: 960125
APPLICATION: WO 96/036 A1 PCT No. AU 94/074 (940748)
PAGES: 111 pp. CODEN: INDEX2 LANGUAGE: English CLASS: A61K-031/70A;
A61K-031/70B; A61K-031/70H DESIGNATED COUNTRIES: AM; AT; AU; BE; BG; BR;
BY; CA; CH; CN; CO; DE; DK; EE; ES; FI; GB; GR; HU; IS; JP; KE; KG; KP; KR;
KZ; LK; LR; LT; LU; LV; MD; MG; MN; MX; MY; NO; NZ; PL; PT; RO; RU; SD; SE;
SG; SI; SK; TJ; TM; TT DESIGNATED REGIONAL: KE; MW; SD; SZ; TG; AT; BE; CH;
DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
CM; GA; GN; ML; MR; NE; SN; TD; TG

10/3,K/16 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online
(c) 2002 ProQuest Info&Learning. All rts. reserv.

01439558 ORDER NO: AADAA-19533739
***INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5* INHIBITS
MYOGENIC DIFFERENTIATION THROUGH AN IGF-DEPENDENT PROCESS**
Author: JAMES, PAYTON LEIGH
Degree: PH.D.
Year: 1995
Corporate Source/Institution: WASHINGTON UNIVERSITY (0252)
Source: VOLUME 56/06-B OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 2987. 188 PAGES

***INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5* INHIBITS
MYOGENIC DIFFERENTIATION THROUGH AN IGF-DEPENDENT PROCESS**

...dependent manner.
Stable transfectants of the C2 cell line were established which constitutively express the coding sequence of IGFBP-5 in either the sense or *antisense* orientation to determine the function of this protein during myogenic differentiation. Forced expression of the *antisense* transcripts caused rapid differentiation as assessed by myotube formation, creatine kinase activity, and the production of myosin heavy chain and the muscle-specific transcription factor...

10/3,K/17 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog Corporation. All rts. reserv.

02322558 PMID: 97604744
Antiproliferative effects of ICI 182780 are partly mediated by upregulation of *insulin*-*like* *growth* *factor* *binding* *protein* *5* (IGFBP-5) (Meeting abstract).
Hynes, Jane; et al ; 1998
Lady Davis Research Inst., Montreal, Quebec H3T 1B4, Canada
Proc Ann Meet Am Ass Cancer Res 1998; 39: 1100-1101
Document Type: MEETING ABSTRACTS
Language: ENGLISH
Main Citation Owner: NCI/NCI
Record type: Completed

Antiproliferative effects of ICI 182780 are partly mediated by upregulation of *insulin*-*like* *growth* *factor* *binding* *protein* *5*

and anti-estrogen-induced growth inhibition. These results indicate that ICI
164,384 enhances anti-proliferative effects of ICI 164,384.

Chemical Name: ICI 164,384; Estradiol; Estrogen Antagonists; *Insulin*-
like *Growth*-*Factor*-*Binding*-*Protein* *B*²; RNA, Messenger

5/3,K/1 (Item 1 from file: 5)
 D:\NOO(K)\FILE 5:R10116 PROVISIONS(R
 10/1/2000 11:00:00 AM 11:00:00 AM

ATTORNS: Filisov Sergei Y(a); Ivanov Sergey V; Yoshino Kiyoshi; Dove Lee F;
Filisova Tatiana M; Higginbotham Kathleen G; Karavanova Irina; Lerman
Michael; Pulatov Alai O

SUMMARY LANGUAGE: English

5/3,K/3 (Item 1 from file: 399)

DIALOG(R) File 399:CA SEARCH(E)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft

LOCATION: Den.

ASSIGNEE: Gene Biotech Aps

PATENT: PCT International ; WO 200231953 A2 DATE: 20020423

APPLICATION: WO 2001DK695 (20011019) *DK 20001571 (20001020) *US PV241840 (20001020)

PAGES: 113 pp. CODEN: FIXXD2 LANGUAGE: English CLASS: C07K-C14/435A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GB; GR; HD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; ME; MG; MK; MN; MW; MX; MY; NZ; OM; PA; PE; PG; PH; PK; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; SM; SN; SR; TD; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; EG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; NG; SN; TD; TG

5/3,K/4 (Item 2 from file: 399)

DIALOG(R) File 399:CA SEARCH(E)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134125934 CA: 134(10)125934z PATENT

IGFBP-5 antisense oligodeoxynucleotide therapy for hormone-regulated tumors

INVENTOR(AUTHOR): Gleave, Martin

LOCATION: Can.,

ASSIGNEE: The University of British Columbia; Miyake, Hideaki

PATENT: PCT International ; WO 200105435 A2 DATE: 20010125

APPLICATION: WO 2000CA853 (20000719) *US PV144495 (19990719)

PAGES: 45 pp. CODEN: FIXXD2 LANGUAGE: English CLASS: A61K-048/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; ME; MG; MK; MN; MW; MX; MY; NZ; OM; PA; PE; PG; PH; PK; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; EG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; NG; SN; TD; TG

3/3,K/3 (Item 1 from file: 399)

CLASS: B. Field: AMERICA SPANISH

© 1999 AMERICAN CHEMICAL SOCIETY. All rights reserved.

134125934 CA: 134(10)125934z PATENT

IGFBP-5 antisense oligodeoxynucleotide therapy for hormone-regulated tumors

INVENTOR: AUTHOR: Gleason, Martin

LOCATION: Can.,

ASSIGNER: The University of British Columbia; Miyake, Hideaki

PATENT: PCT International ; W. 2001/049741 A1 DATE: 2001/01/23

APPLICATION: WO 2001/049741 A1 2001/01/23

PAGES: 48 pp. CODEN: PXXXXX LANGUAGE: English CLASS: A61K-048/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DO; EE; ES; FI; GB; GD; GE; GR; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LG; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; NE; NL; NO; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TR; TT; TZ; UA; UG; US; VE; VN; YU; ZA; ZW; AM; AG; BY; KG; KZ; MD; RU; TC; TM DESIGNATED REF: KAL; GR; GM; KE; LS; MW; MO; SI; SL; SZ; TD; TG; TW; AT; BE; CH; CY; DE; DK; EE; FI; FR; GR; HR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MK; NE; SN; TD; TG

```

... Deleted Exhibition Record
01: 1977-1984 Philippe Brous
Tshw files; 1971-1984-111
File 1:Biologic Previews R 1984-2002 Aug W1
(c) 2002 ELISIS
File 6:INIST 1984-2002 Aug W1
(c) 2002 INIST, Intl Copyright All Rights Res
File 14:Biologic Previews R 1977-2002 Aug W1
(c) 2002 Engineering Info. Inc.
File 34:SciSearch(R) Cited Ref Sci 1974-2002 Aug W3
(c) 2002 Inst for Sci Info
File 66:Inside Conferences 1997-2002/Aug W2
(c) 2002 INIST all rts. reserv.
File 71:ELSEVIER BIOBASE 1994-2002/Aug W1
(c) 2002 Elsevier Science B.V.
File 73:EMBASE 1974-2002/Aug W2
(c) 2002 Elsevier Science B.V.
File 76:Life Sciences Collection 1982-2002/Jul
(c) 2002 Cambridge Sci Abs
File 94:BIOT-EBplus 1986-2002/Jun W3
(c)2002 Japan Science and Tech Corp(JST)
File 98:General Sci Abs/Full-Text 1984-2002/Jun
(c) 2002 The HW Wilson Co.
File 99:Wilson Appl. Sci. & Tech Abs 1986-2002/Jun
(c) 2002 The HW Wilson Co.
File 135:NewsRx Weekly Reports 1995-2002/Aug W1
(c) 2002 NewsRx
File 143:Biocl. & Agric. Index 1983-2002/Jun
(c) 2002 The HW Wilson Co
File 144:Pascal 1973-2002/Aug W2
(c) 2002 INIST/CNRS
File 155:MEDLINE(R) 1966-2002/Aug W2
File 172:EMBASE Alert 2002/Aug W2
(c) 2002 Elsevier Science B.V.
File 266:EBRIIP 2002/Jun
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotech Abs 1970-2002/Jun
(c) 2002 DECHEMA
File 357:Derwent Biotech Res. 1982-2002/June W1
(c) 2002 Thomson Derwent & ISI
File 358:Current BioTech Abs 1983-2001/Oct
(c) 2001 DECHEMA
File 369:New Scientist 1994-2002/Jul W2
(c) 2002 Reed Business Information Ltd.
File 370:Science 1976-1999/Jul W3
(c) 1999 AAAS
File 399:CA SEARCH(R) 1967-2002/UD=13767
(c) 2002 AMERICAN CHEMICAL SOCIETY
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1999 Inst for Sci Info
File 4:Environ. Lib. R 1974-1984/Jun
File 111:Environ. Lib. R 1974-1984/Jun
(c) 2002 Cambridge Scientific Abstracts
File 112:Environ. Lib. R 1974-1984/Jun
(c) 2002 CAB International
File 66:Env.Rib. 1977-2002/Jun
(c) 2002 Internal Academy at Santa Barbara
File 77:Conference Papers Index 1978-2002/Jul
(c) 2002 Cambridge Sci Abs
File 1:Environ. Lib. R 1974-1984/Jun
(c) 2002 Cambridge Scientific Abstracts
File 111:Environ. Lib. R 1974-1984/Jun
(c) 2002 Cambridge Scientific Abstracts
File 112:Environ. Lib. R 1974-1984/Jun
(c) 2002 Cambridge Scientific Abstracts

```


File 441:SI:ATIS:1981-1982/Jul-Aug
 (c) 2002 Sport Information Resource Centre
 File 442:AM:ATIS:1981-1982/Jul-Aug
 (c) 2002 Action Potential
 File 443:TH:HealthWellness:1981-1982/Jul-Aug
 (c) 2002 The Gale Group
 File 444:J:J:1981-1982/Jul-Aug
 (c) 2002 Dialog Corporation
 File 445:Allied & Complementary Medicine:1981-1982/Jul-Aug
 (c) 2002 RHCIS
 File 446:AMA:Journals:1981-1982/Jul-Aug
 (c) 2002 Amer Med Assn -FAMS/MASS apply
 File 447:New England Journal of Med.:1981-1982/Jul-Aug
 (c) 2002 Mass. Med. Soc.
 File 448:ExtraMED:1981-1982/Jul-Aug
 (c) 2002 Informania Ltd.

Set	Items	Description
S1	336	IGFBP5 OR (IGF (W) BPL)
S2	13	S1 (S) (ANTISENSE OR RIBOZYME?)
S3	3	RD (unique items)
S4	14	S1 AND (ANTISENSE OR RIBOZYME?)
S5	4	RD (unique items)
S6	1907	INSULIN (W) LIKE (W) GROWTH (W) FACTOR (W) BINDING (W) PRO- TEIN (W) 5
S7	11	S6 (S) (ANTISENSE OR RIBOZYME?)
S8	4	RD (unique items)
S9	42	S6 AND (ANTISENSE OR RIBOZYME?)
S10	17	RD (unique items)

James, Fayon L.
Stewart, Claire E. H; Rotwein, Peter
The Journal of Cell Biology / Cell Biol. v. 133 no. 1 May 1996 p. 683-93
SPECIAL FEATURES: Full Text ISSN: 0021-9525
LANGUAGE: English
COUNTRY OF PUBLICATION: United States

ABSTRACT: The function of insulin-like growth factor binding protein-5 (IGFBP-5) in myogenesis, a process stimulated by IGFs, was studied using C2 myoblasts. Compared with vector-transfected control cells, C2 myoblasts expressing an IGFBP...

...extracellular matrix during proliferation and subsequently did not differentiate normally. In contrast, differentiation was premature and more extensive in the presence of an IGFBP-5 antisense transcript. The inhibitory effects of high IGFBP-5 expression were overcome by exogenous IGFs. These findings are in agreement with a model in which IGFBP...

8/3,K/3 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft

LOCATION: Den.

ASSIGNEE: Como Biotech Aps

PATENT: PCT International ; WO 200232953 A2 DATE: 20020425

APPLICATION: WO 2001DK695 (20011019) *DK 20031571 (20031020) *US PV241840 (20031020)

PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/435A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; ME; MK; MN; MW; MX; MY; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3,K/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

124270541 CA: 124(20)270541s PATENT

Use of antisense nucleic acids/analogs inhibiting growth factor-mediated cell proliferation for treatment of proliferative and/or inflammatory skin disorders

INVENTOR(AUTHOR): Kottmann, Hans-Joachim; Kottmann, Hans-Joachim

LOCATION: Australia

ASSIGNEE: Royal Children's Hospital Research Foundation

PATENT: PCT International ; WO 9601696 A1 DATE: 19960125

APPLICATION: WO 9401111 (19940111) *AU 640715 (19940715)

PAGES: 115 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-001/70A;

C07K-001/40B; C07K-001/40B DESIGNATED COUNTRIES: AM; AT; AU; BB; BG; BR; BY; BF; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG